| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Mouse β-CTx concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Mouse β-CTx. During the reaction, Mouse β-CTx in the sample or standard competes with a fixed amount of Mouse β-CTx on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Mouse β-CTx. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Mouse β-CTx in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 46.88 pg/mL |
|---|---|
| Detection Range | 78.13-5000 pg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Mouse |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Mouse β-CTx in samples.No significant cross-reactivity or interference between Mouse β-CTx and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 46.88 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant β-CTx standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Smart Nanosacrificial Layer on the Bone Surface Prevents Osteoporosis through Acid–Base Neutralization Regulated Biocascade Effects (2020) Journal of the American Chemical Society. 10.1021/jacs.0c07309
Epigenetic Targeting of Senescent Cells Prevents the Deleterious Effects of Obstructive Sleep Apnea on Growing Skeleton (2025) Advanced Science. 10.1002/advs.202502697
Bio-orthogonal engineered peptide: A multi-functional strategy for the gene therapy of osteoporotic bone loss (2023) BIOMATERIALS. 10.1016/j.biomaterials.2023.122352
Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production (2026) EXPERIMENTAL AND MOLECULAR MEDICINE. 10.1038/s12276-026-01682-7
Enhanced homing of mesenchymal stem cells for in situ niche remodeling and bone regeneration (2024) Nano Research. 10.1007/s12274-024-6715-1
Crebanine protects against ovariectomy-induced bone loss by targeting Sirt1 to interfere with NF-κB acetylation and ROS activity (2025) Journal of Pharmaceutical Analysis. 10.1016/j.jpha.2025.101426
Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss (2024) Cell Communication and Signaling. 10.1186/s12964-024-01525-w
Safranal inhibits estrogen-deficiency osteoporosis by targeting Sirt1 to interfere with NF-κB acetylation (2023) PHYTOMEDICINE. 10.1016/j.phymed.2023.154739
Thiaplakortone B attenuates RANKL‐induced NF‐κB and MAPK signaling and dampens OVX‐induced bone loss in mice (2022) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2022.113622
PKC-δ deficiency in B cells displays osteopenia accompanied with upregulation of RANKL expression and osteoclast–osteoblast uncoupling (2020) Cell Death & Disease. 10.1038/s41419-020-02947-3
DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis (2015) Science Signaling. 10.1126/scisignal.2005835
Hymenialdisine: A Marine Natural Product That Acts on Both Osteoblasts and Osteoclasts and Prevents Estrogen-Dependent Bone Loss in Mice (2020) JOURNAL OF BONE AND MINERAL RESEARCH. 10.1002/jbmr.4025
Cedrol, a Ginger-derived sesquiterpineol, suppresses estrogen-deficient osteoporosis by intervening NFATc1 and reactive oxygen species (2023) INTERNATIONAL IMMUNOPHARMACOLOGY. 10.1016/j.intimp.2023.109893
Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein (2014) BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 10.1016/j.bbadis.2014.04.018
Anoctamin 5 mutation leads to abnormal bone homeostasis of GDD by regulating AMPK-dependent glucose metabolism (2026) Frontiers in Endocrinology. 10.3389/fendo.2026.1703491
Irisin reduces senile osteoporosis by inducing osteocyte mitophagy through Ampk activation (2024) iScience. 10.1016/j.isci.2024.111042
A single acute alcohol intoxication before fracture insult causes long-term elevated systemic RANKL and OPG levels in young adult mice (2025) Scientific Reports. 10.1038/s41598-025-09240-3
A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast function (2025) ARCHIVES OF GERONTOLOGY AND GERIATRICS. 10.1016/j.archger.2025.106020
Aging Influences Fracture Healing on the Cellular Level and Alters Systemic RANKL and OPG Concentrations in a Murine Model (2024) Advanced Biology. 10.1002/adbi.202300653
